Idm Pharma Inc

Idm Pharma — Technical Presentation (June 2007)

22 slides from Idm Pharma's technical presentation, Jun 5, 2007

  1. Slide 1: Clinical and Immunological Responses in Patients with Malignant Melanoma Treated with a Dendritic Cell-based Vaccine

    Clinical and Immunological Responses in Patients with Malignant Melanoma Treated with a Dendritic Cell^based Vaccine: Preliminary Report from a Multi-institutional Phase II Clinical Trial MI Ross, LH Camacho; EM Hersh, CK Brown, J Richards, P Mitsky, E Wasserman, SM Lee, N Bercovici, D Landais, A Ri

  2. Slide 2: Background

    Background Immunogenicity of Melanoma Spontaneous tumor regression Vitiligo Antitumor activity of cytokine therapy Cytotoxic T cells from patients are active in-vitro

  3. Slide 3: Background (cont'd): Dendritic Cell Vaccines

    Background (cont'd) Dendritic Cell Vaccines Functional antigen presentation Induction and maintenance of antitumor immune responses Antigens from lysates or whole cells may improve immunogenicity Objective Responses ~ 10-15% with tumor cell-pulsed Dendritic Cells

  4. Slide 4: IDD-3 vaccine

    IDD-3 vaccine Type: Cell Drug Production: Patient Dendritic Cells (DC) loaded with cell lysates from 3 allogeneic melanoma cell lines: M44, COLO829 and SK-MEL-28 Storage: Cryopreserved at -120°C, one lot of 20 doses Mode of administration: Intradermal + Subcutaneous

  5. Slide 5: Background (cont'd): Clinical Development

    Background (cont'd) Clinical Development: Phase I/II in 15 metastatic patients: 1 CR and 1 SD 4 patients overall survival greater than 20 months Salcedo et al. Cancer Immunol Immunother. 2005 Phase I/II in 49 stage IV patients: 10 SD Gorin et al. ASCO 2005 Phase II in 33 patients with M1a, M1b and i

  6. Slide 6: Study Design

    Study Design Phase II, Open Label, Single Arm Objectives Clinical activity Immunologic activity Safety Patient Population Stage IV - M1a, M1b- and in transit lesion LDH < 1.5 ULN Measurable or evaluable disease Prior chemotherapy, biotherapy (except vaccines) accepted Progressive disease before stud

  7. Slide 7: GMP Manufacturing Process

    GMP Manufacturing Process IDD-3 lymphocytes Elutriated cells purification GMP 7 days culture, addition of cytokines Dendritic Cells Monocytes & lymphocytes apheresis Allogenic melanoma tumor cell lysate Maturation

  8. Slide 8: Study Design

    Study Design Screening Apheresis Patient follow-up: Safety, immune response, clinical W0 W2 W4 W6 W8 W10 W12 W16 W22 W24 W36 W48 W-6 W-4 10 ID and 2 SC at each immunization* Partial Apheresis Partial Apheresis 70 ml blood 70 ml blood 70 ml blood 70 ml blood 5 ml blood * Patients with documented stab

  9. Slide 9: Demographics

    Demographics n = 33 Age, median (range) 59 (27-85) Sex M/F 19/14 LDH < 1.5 ULN 33 (100%) PS 0/1/2 22/10/1 Stage M1a M1b In transit M1c (liver) 7 (21%) 16 (48%) 9 (27%) 1 (3%) Prior Treatments Chemotherapy Biotherapy Radiotherapy ILP (Isolated Limb Perfusion) No previous systemic therapy 10 (30%) 14

  10. Slide 10: Patient Status

    Patient Status 38 patients enrolled 5 withdrawals before treatment 3 before the first injection due to disease progression 2 for apheresis failures 33 started treatment 32 reached week 8 disease assessment or further 25 reached week 12 (received 6 injections) 15 reached week 22 (received 8 injection

  11. Slide 11: Efficacy

    Efficacy n=33 PFS OS Median from time of apheresis (95% CI) 4.8 months (4.0-5.7) Not reached Survival at 9mo: 70% Patients evaluable for response (RECIST) : 30 1 CR , 2 PR, (ORR: 10%) Tumor Control 6 additional SD Tumor Control rate (CR+PR+ SD): 30% Median follow-up from apheresis: 11.7 months (2.9-

  12. Slide 12: Summary of Clinical Responders

    Summary of Clinical Responders Patient Gender/Age Stage Prior treatment Best RECIST Response Time from prior treatment to PD (month) PFS from apheresis (month) # 2 Male/ 60 y M1a Surgery (Wide excisions) CR 5 + 26.5 (a) # 7 Female/ 44 y M1b Surgery-ILP (Melphalan) SD NED 14 + 23.7 (a) # 10 Female/ 7

  13. Slide 13: Clinical Activity - Patient #10 (PR)

    Clinical Activity - Patient #10 (PR) BASELINE - AUG 2005

  14. Slide 14: Histology

    Histology Courtesy of Victor Prieto, MD (MDACC) Target 6 Week 24 Target 6 Week 32 patient 10 (PR)

  15. Slide 15: Histological Assessment

    Histological Assessment Patients Tumor Location Procedure Results Patient Status # 10 In-transit Biopsy Negative PR # 7 Skin Lung Removal Resection Negative Residual SD then NED # 11 Lung Thoracotomy Residual SD then NED # 38 Skin Biopsy Negative PR 2 patients achieved pathological CR after resectio

  16. Slide 16: Detection of TAA-specific CD8+ T cells after peptide in vitro sensitization

    Detection of TAA-specific CD8+ T cells after peptide in vitro sensitization D -1 D0 PBMC thawing Stimulation with Pools of TAA-peptides (9mers) D1 Addition of IL-7/IL-15 D6 D11 D14 Intracellular Cytokine Staining (5h) gated on CD3+CD8+ Detection of specific CD8 In vitro sensitization IFN-^ CD107 Poo

  17. Slide 17: Immune Response Against Multiple-Peptides Pool

    Immune Response Against Multiple-Peptides Pool control HIV Pool 4 MelanA, NYESO1, Prame, ... Pool 1 gp100 IFN-g (ICS) CD107 Pre Post #6 Post #8 10 0 10 1 10 2 10 3 10 4 0.2% 0.6% 1.0% 18.8% 2.8% 10 0 10 1 10 2 10 3 10 4 0.1% 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 0.1% 10.6% 6.8% Patient #

  18. Slide 18: Overview of Immune Responses

    Overview of Immune Responses Immune response to vaccination Patient's ID Clinical status Boosted / Induced responses (n=18) # 20 PD Boosted / Induced responses (n=18) # 19 PD Boosted / Induced responses (n=18) # 2 CR Boosted / Induced responses (n=18) # 21 PD Boosted / Induced responses (n=18) # 16

  19. Slide 19: Tumor-specific CTL

    Tumor-specific CTL 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 0.20% 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 0.01% 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 0.01% 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 1.00% Pre Post #6 Pool 4 (MelanA, ...) IFN-g (ICS) CD107 Tetram

  20. Slide 20: Summary

    Summary Efficacy Tumor Control 1 CR, 2 PR and 6 SD PFS: 4.8 months (from apheresis) 21 patients alive (9.5-26.5 months from apheresis) Complete Histological Regression in target sites Immune response 18/29 (62%) showing increased reactivity post-vaccination All 3 CR/PR and 2 of 6 SD had increased re

  21. Slide 21: Conclusions

    Conclusions Vaccination with IDD-3 /UVIDEMO can modify the natural history of low volume metastatic melanoma in some patients Association of clinical activity and immune response was observed. Other immunologic surrogates are needed Further development is warranted

  22. Slide 22: Collaborators

    Collaborators Investigators L.H. Camacho M D Anderson Cancer Center, Houston, TX E.M. Hersh Arizona Cancer Center, Tucson, AZ C.K. Brown Hillman Cancer Center, Pittsburgh, PA J. Richards Lutheran General Cancer Care Center Park Ridge, IL A. Ribas UCLA - Los Angeles, CA IDM Pharma S.M. Lee N. Bercovi

IDM Pharma — Technical Presentation (June 2007) on 6ix